Literature DB >> 29408529

Endovascular recanalization for chronic symptomatic intracranial vertebral artery total occlusion: Experience of a single center and review of literature.

Peng Gao1, Yabing Wang2, Yan Ma2, Qi Yang3, Haiqing Song4, Yanfei Chen2, Liqun Jiao5, Adnan I Qureshi6.   

Abstract

OBJECTIVE: The optimal treatment of chronic symptomatic total occlusion of the intracranial vertebral artery (ICVA) remains undefined. We report a single-center experience of endovascular recanalization for patients with chronic symptomatic ICVA occlusion who were refractory to medical therapy.
METHODS: From Jan 2009 to Jan 2017, we retrospectively reviewed 14 consecutive patients presenting with recurrent symptoms attributed to the chronic ICVA occlusion. We searched previous literature using PubMed databases during the same period as comparison.
RESULTS: Eleven patients out of 14 presented initial symptoms to intervention less than 90days. The occlusion course was extrapolated on simultaneous two-vessel injection angiography or high-resolution MR imaging (HRMRI) in 13 cases. Nine patients had the occlusion beyond the origin of posterior inferior cerebellar artery (PICA) and 5 had the occlusion proximal to the PICA origin. The technical success rate of recanalization was 85.7% (12/14). Two patients (14.3%, 2/14) had peri-procedural complications: 1 developed TIA and 1 presented with perforator occlusion syndrome. Using the keyword-based search, we identified 6 studies at the same period. A total of 34 patients underwent recanalization with the successful recanalization rate at 94.1%, peri-procedural complication rate at 17.6% and mortality at 2.9%, respectively.
CONCLUSION: Our single-center study illustrated the feasibility and safety of ICVA recanalization. Great care should be taken as revascularization is of high risk. When patient selection, occlusion course and stage as well as neuroimaging evaluation are considered, endovascular recanalization may be a useful therapeutic modality.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Chronic total occlusion; Endovascular treatment/therapy; Recanalization; Vertebral artery; Vertebral artery insufficiency

Mesh:

Year:  2018        PMID: 29408529     DOI: 10.1016/j.neurad.2017.12.023

Source DB:  PubMed          Journal:  J Neuroradiol        ISSN: 0150-9861            Impact factor:   3.447


  5 in total

Review 1.  Invasive Management of Vertebrobasilar Artery Stenosis and Occlusion: A Meta-Analysis on Efficacy and Safety Endpoints.

Authors:  Nso Nso; Mahmoud Nassar; Mia Trimingham; Yolanda Mbome; Anthony Lyonga Ngonge; Solomon O Badejoko; Shahzad Akbar; Atika Azhar; Sofia Lakhdar; Muhammad Ghallab; Laura M Guzman Perez; Vincent Rizzo; Most Sirajum Munira
Journal:  Cureus       Date:  2022-05-05

2.  Simultaneous PET-MRI imaging of cerebral blood flow and glucose metabolism in the symptomatic unilateral internal carotid artery/middle cerebral artery steno-occlusive disease.

Authors:  Bixiao Cui; Tianhao Zhang; Yan Ma; Zhongwei Chen; Jie Ma; Lei Ma; Liqun Jiao; Yun Zhou; Baoci Shan; Jie Lu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-06       Impact factor: 9.236

3.  Endovascular recanalization for symptomatic intracranial internal carotid and middle cerebral artery occlusion lasting longer than 72 h: Experience in a single center.

Authors:  Guangwen Li; Peng Liu; Wentao Gong; Xianjun Zhang; Yong Zhang; Naidong Wang
Journal:  Brain Circ       Date:  2021-12-21

4.  Endovascular Recanalization of Symptomatic Nonacute Intracranial Internal Carotid Artery Occlusion: Proposal of a New Angiographic Classification.

Authors:  F Gao; X Sun; X Guo; D Li; G D Xu; Z R Miao
Journal:  AJNR Am J Neuroradiol       Date:  2020-12-24       Impact factor: 3.825

5.  Staged Endovascular Treatment for Symptomatic Occlusion Originating From the Intracranial Vertebral Arteries in the Early Non-acute Stage.

Authors:  Hongzhou Duan; Li Chen; Shengli Shen; Yang Zhang; Chunwei Li; Zhiqiang Yi; Yingjin Wang; Jiayong Zhang; Liang Li
Journal:  Front Neurol       Date:  2021-06-16       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.